7 results on '"S. N. Mothi"'
Search Results
2. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting
- Author
-
M Selvaraj, J Maheshmanisha, Anandha Chitra, S Vennila, N Poornagangadevi, Soumya Swaminathan, B B Rewari, P. K. Bhavani, M Tamizhselvan, L Sekar, Chandrasekaran Padmapriyadarsini, Upasna Agarwal, K Nandagopal, S N Mothi, and Devarajulu Reddy
- Subjects
Adult ,IPT ,Pediatrics ,medicine.medical_specialty ,Tuberculosis ,Antitubercular Agents ,programmatic settings ,India ,HIV Infections ,Pilot Projects ,General Biochemistry, Genetics and Molecular Biology ,Hiv infected ,parasitic diseases ,Isoniazid ,Medicine ,Humans ,Prospective Studies ,people living with HIV ,Adverse effect ,tuberculosis prevention ,business.industry ,Incidence (epidemiology) ,Incidence ,General Medicine ,medicine.disease ,Antiretroviral therapy ,Confidence interval ,antiretroviral therapy - ipt - people living with hiv - programmatic settings - tuberculosis prevention ,Preventive therapy ,Original Article ,business ,medicine.drug - Abstract
Background & objectives: As India and other developing countries are scaling up isoniazid preventive therapy (IPT) for people living with HIV (PLHIV) in their national programmes, we studied the feasibility and performance of IPT in terms of treatment adherence, outcome and post-treatment effect when given under programmatic settings. Methods: A multicentre, prospective pilot study was initiated among adults living with HIV on isoniazid 300 mg with pyridoxine 50 mg after ruling out active tuberculosis (TB). Symptom review and counselling were done monthly during IPT and for six-month post-IPT. The TB incidence rate was calculated and risk factors were identified. Results: Among 4528 adults living with HIV who initiated IPT, 4015 (89%) successfully completed IPT. IPT was terminated in 121 adults (3%) due to grade 2 or above adverse events. Twenty five PLHIVs developed TB while on IPT. The incidence of TB while on IPT was 1.17/100 person-years (p-y) [95% confidence interval (CI) 0.8-1.73] as compared to TB incidence of 2.42/100 p-y (95% CI 1.90-3.10) during the pre-IPT period at these centres (P=0.017). The incidence of TB post-IPT was 0.64/100 p-y (95% CI 0.04-1.12). No single factor was significantly associated with the development of TB. Interpretation & conclusions: Under programmatic settings, completion of IPT treatment was high, adverse events minimal with good post-treatment protection. After ruling out TB, IPT should be offered to all PLHIVs, irrespective of their antiretroviral therapy (ART) status. Scaling-up of IPT services including active case finding, periodic counselling on adherence and re-training of ART staff should be prioritized to reduce the TB burden in this community.
- Published
- 2020
3. Mitochondrial DNA content of peripheral blood mononuclear cells in ART untreated & stavudine/zidovudine treated HIV-1-infected patients
- Author
-
Pachamuthu Balakrishnan, S. Poongulali, Rao B. Srirama, Shanmugam Saravanan, Jayaseelan Boobalan, Dhakshinamoorthy Subashini, Devaraj A. Chitra, Suniti Solomon, Sunil S. Solomon, S. N. Mothi, and Thongadi Ramesh Dinesha
- Subjects
0301 basic medicine ,Adult ,Male ,Mitochondrial DNA ,lcsh:Medicine ,HIV Infections ,mitochondrial DNA ,Peripheral blood mononuclear cell ,Asymptomatic ,DNA, Mitochondrial ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Zidovudine ,Antiretroviral Therapy, Highly Active ,mitochondrial dysfunction ,medicine ,Humans ,ART naïve ,business.industry ,lcsh:R ,Stavudine ,virus diseases ,HIV ,toxicity ,General Medicine ,Middle Aged ,medicine.disease ,peripheral blood mononuclear cells ,030112 virology ,nucleoside reverse transcriptase inhibitors ,Mitochondrial toxicity ,030104 developmental biology ,Toxicity ,Immunology ,HIV-1 ,Leukocytes, Mononuclear ,Biomarker (medicine) ,Reverse Transcriptase Inhibitors ,Original Article ,Female ,ART naïve - HIV - mitochondrial dysfunction - mitochondrial DNA - nucleoside reverse transcriptase inhibitors - peripheral blood mononuclear cells - toxicity ,medicine.symptom ,business ,medicine.drug - Abstract
Background & objectives: Nucleoside reverse transcriptase inhibitors (NRTIs) are known to cause mitochondrial toxicity. This study was done to estimate mitochondrial DNA (mtDNA) content of peripheral blood mononuclear cells (PBMCs) among human immunodeficiency virus (HIV) infected, NRTI treated and antiretroviral therapy (ART)-naïve patients and evaluate the utility of mtDNA content as a biomarker of mitochondrial toxicity. Methods: mtDNA content in PBMCs of 57 HIV-infected ART untreated and 30 ART treated with stavudine (d4T) or zidovudine (AZT) containing regimen were compared against 24 low-risk healthy controls (LoRHC). Results: There was a significant (P=0.01) reduction in mtDNA content among HIV-infected (104; 80-135) compared to LoRHC (127; 110-167), and it was the same in both the treated (104.8; 88-130) and untreated patients (104.7; 78-142). mtDNA significantly (P=0.014) declined in ART treated patients symptomatic for toxicity (97; 74-111) than the asymptomatic patients (128; 103- 153). Interpretation & conclusions: mtDNA depletion in PBMCs was evident among HIV-infected individuals on ART. Moreover, as mtDNA content was reduced among the patients symptomatic for toxicity than the asymptomatic in both the HIV-infected groups, the current study supports mtDNA content of PBMCs to serve as a biomarker of mitochondrial dysfunction induced by NRTI and HIV. Longitudinal studies with a large sample need to be done to confirm these findings.
- Published
- 2018
4. Paediatric HIV - trends & challenges
- Author
-
S. Karpagam, V. H. T. Swamy, S. N. Mothi, S M Sarvode, and M Lala Mamatha
- Subjects
trends ,medicine.medical_specialty ,Pediatrics ,psychosocial issues ,Pediatric hiv ,HIV Infections ,Review Article ,General Biochemistry, Genetics and Molecular Biology ,early infant diagnosis ,Antiretroviral Therapy, Highly Active ,Medicine ,Humans ,Disease management (health) ,Challenges ,Intensive care medicine ,Child ,clinical manifestations ,business.industry ,Transmission (medicine) ,Immunization Programs ,Disease Management ,Infant ,paediatric HIV ,General Medicine ,medicine.disease ,Antiretroviral therapy ,Infectious Disease Transmission, Vertical ,Malnutrition ,clinical diagnosis ,nutrition ,Spite ,HIV-1 ,Holistic management ,immunization in children with HIV ,business ,Psychosocial ,management - Abstract
With the availability of antiretroviral therapy (ART), HIV infection, which was once considered a progressively fatal illness, has now become a chronic treatable condition in children, as in adults. However, the challenges these children are forced to face are far more daunting. The most significant shortcoming in the response to paediatric HIV remains the woefully inadequate prevention of mother-to-child transmission (PMTCT), allowing a large number of children to be born with HIV in the first place, in spite of it being largely preventable. In the west, mother-to-child transmission has been virtually eliminated; however, in resource-limited settings where >95 per cent of all vertical transmissions take place, still an infected infants continue to be born. There are several barriers to efficient management: delayed infant diagnosis, lack of appropriate paediatric formulations, lack of skilled health personnel, etc. Poorly developed immunity allows greater dissemination throughout various organs. There is an increased frequency of malnutrition and infections that may be more persistent, severe and less responsive to treatment. In addition, these growing children are left with inescapable challenges of facing not only lifelong adherence with complex treatment regimens, but also enormous psychosocial, mental and neuro-cognitive issues. These unique challenges must be recognized and understood in order to provide appropriate holistic management enabling them to become productive citizens of tomorrow. To address these multi-factorial issues, there is an urgent need for a concerted, sustainable and multi-pronged national and global response.
- Published
- 2011
5. Differences in Evolution of HIV-1 Subtype C Reverse Transcriptase Between Children and Adults Likely Explained by Maturity of Cytotoxic T-Lymphocyte Responses
- Author
-
Sunil S. Solomon, Jayaseelan Boobalan, Bagavathi Kausalya, Pachamuthu Balakrishnan, S. N. Mothi, Shanmugam Saravanan, Kailapuri G. Murugavel, Davey M. Smith, Poongulali Selvamuthu, Suniti Solomon, Selvamurthi Gomathi, and Nagalingeswaran Kumarasamy
- Subjects
Adult ,Male ,Genotype ,Immunology ,Clinical Sciences ,Molecular Sequence Data ,Human immunodeficiency virus (HIV) ,Drug resistance ,Biology ,medicine.disease_cause ,Evolution, Molecular ,Negative selection ,Virology ,Genetic variation ,medicine ,Sequence Note ,Cytotoxic T cell ,Humans ,Selection, Genetic ,Child ,Extramural ,Genetic Variation ,Sequence Analysis, DNA ,Middle Aged ,Reverse transcriptase ,HIV Reverse Transcriptase ,Infectious Diseases ,HIV-1 ,Female ,T-Lymphocytes, Cytotoxic - Abstract
In this study HIV-1 subtype C-infected adults demonstrated higher purifying selection on their viral populations in reverse transcriptase (RT) than infected children. This difference is likely explained by more mature cytotoxic T-lymphocyte responses in adults, which may have implications for the development of drug resistance in the RT region.
- Published
- 2015
- Full Text
- View/download PDF
6. Mitochondrial dysfunction among HIV-1 infected patients of South India and evaluation of mitochondrial DNA as a biomarker of mitochondrial toxicity
- Author
-
Shanmugam Saravanan, P. Balakrishnan, Jayaseelan Boobalan, Selvamurthi Gomathi, Sunil S. Solomon, S. N. Mothi, L. Samuel, Chinnambedu Ravichandran Swathirajan, R. Srirama, Thongadi Ramesh Dinesha, Devaraj A. Chitra, Dhakshinamoorthy Subashini, S.S. Solomon, and S. Poongulali
- Subjects
0301 basic medicine ,Microbiology (medical) ,Mitochondrial DNA ,business.industry ,Human immunodeficiency virus (HIV) ,virus diseases ,General Medicine ,social sciences ,030204 cardiovascular system & hematology ,medicine.disease_cause ,medicine.disease ,03 medical and health sciences ,Mitochondrial toxicity ,030104 developmental biology ,0302 clinical medicine ,Infectious Diseases ,Cancer research ,Medicine ,Biomarker (medicine) ,population characteristics ,business ,geographic locations - Full Text
- View/download PDF
7. Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India.
- Author
-
N. Kumarasamy, Kartik K. Venkatesh, Bella Devaleenol, S. Poongulali, S. N. Mothi, and Suniti Solomon
- Subjects
HIV-positive persons ,JUVENILE diseases ,HIGHLY active antiretroviral therapy - Abstract
HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with >18 months of follow-up on HAART at a tertiary HIV care program. The median CD4 cell count at enrolment was 290 cells μlâ1 and at treatment initiation was 225 cells μlâ1. Patients demonstrated a significant rise in their CD4 cell counts between treatment initiation and after 6 months (701 cells μlâ1; p = 0.007), 12 months (741 cells μlâ1; p = 0.037), and 18 months of therapy (718 cells μlâ1; p = 0.005). The most common adverse events to therapy were nausea (20.9%) and rash (25.4%). Over one-fifth of patients (25.4%) substituted therapy due to toxicities and 19.4% of patients switched to second-line protease inhibitor-containing regimens. In this South Indian pediatric cohort, generic HAART was safe, effective and relatively well tolerated. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.